news & meetings - latest announcements & happenings | oneAMYLOIDOSISvoice
ATTR-Wild Type And Hereditary (Familial) Amyloidosis Support Group Meeting
Happenings

ATTR-Wild Type and Hereditary (Familial) Amyloidosis Support Group Meeting

The Amyloidosis Support Group (ASG) has been holding this biennial support meeting since 2009. This October we expect 500 patients and caregivers from 44 states and Canada. We will have amyloidosis researchers and clinicians ("amyloidologists") along with clinical trial liaisons. We have added a "Meet & Greet" to the Friday night preceding the event.
 
When:
October 25-27, 2019
 
Where:
Hilton Rosemont/Chicago O'Hare 
5550 N River Road

Rosemont, Illinois, United States

Oct 25, 2019
Prothena Reports Results From The Phase 3 VITAL Amyloidosis Study Of NEOD001 (Birtamimab) In AL Amyloidosis
Clinical Trials and Research

Prothena Reports Results From the Phase 3 VITAL Amyloidosis Study of NEOD001 (Birtamimab) in AL Amyloidosis

Prothena Corporation PLC, a clinical-stage neuroscience company, today reported final results from the Phase 3 VITAL Amyloidosis study of NEOD001 (birtamimab) in newly diagnosed, treatment naive patients with AL amyloidosis and cardiac dysfunction (N=260), which was discontinued in 2018. The final hazard ratio (HR) for the composite primary endpoint (time to all-cause mortality or time to cardiac hospitalization more than 90 days after first infusion of study drug) of 0.835 (95% CI: 0.5799, 1.2011; p=0.3300) was consistent with the futility analysis reported in April 2018.
 
Post hoc analyses of all-cause mortality revealed a potential survival benefit favoring NEOD001 in the category of patients at highest risk for early mortality (Mayo Stage IV, n=77) with a HR of 0.544 (95% CI: 0.2738, 1.0826; p=0.0787). This potential survival benefit was more pronounced in Mayo Stage IV patients during the initial 12 months of treatment, with a HR of 0.498 (95% CI: 0.2404, 1.0304; p=0.0556).
 
Apr 18, 2019

    The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

    Close